Brenntag reports Q2 2025 results below expectations
Persistently challenging market conditions drove Brenntag’s Q2 2025 results lower, with demand softening across ingredients and basic chemicals.
GERMANY – Brenntag, a chemicals and ingredients distribution company, reported a challenging second quarter of 2025 as macroeconomic uncertainty, weak customer sentiment, and unfavourable EUR/USD exchange rates weighed on results.
Group operating gross profit declined 1.9% to EUR 974.3 million (USD 1,138 million), with operating EBITA down 13.9% to EUR 246.4 million (USD 288 million).
Both divisions, Brenntag Specialities and Brenntag Essentials, faced slowing demand and pricing pressure across key end markets.
Specialities, which includes high-value ingredients for Life Science and Material Science applications, posted an operating gross profit of EUR 278.2 million (USD 325 million), down 3.3% year on year.
Within Life Sciences, the Pharma business showed resilience, but Nutrition and Beauty & Care weakened, particularly in the Americas.
Material Science continued to be constrained by a high-interest-rate environment, dampening construction and infrastructure activity.
Operating EBITA in Specialities dropped 11.2% to EUR 98.8 million (USD 116 million) despite improved gross profit per unit from active margin management.
The Essentials division, which supplies large-volume industrial and basic ingredients, achieved a slightly stronger gross profit margin relative to sales.
Operating gross profit declined 1.3% to EUR 696.1 million (USD 813 million) as pricing pressure offset modest volume gains in EMEA, Latin America, and APAC.
Division EBITA fell 13.1% to EUR 177.1 million (USD 207 million).
Brenntag continues to execute its comprehensive cost containment program, generating EUR 30 million (USD 35 million) in quarterly savings and staying on track to reach EUR 300 million (USD 351 million) annual cost reductions by 2027.
Management also advanced its M&A strategy, acquiring mcePharma to expand into the fast-growing EMEA biopharma market and adding GSZ Kaiserslautern to enhance hazardous substance storage capabilities for the Essentials network.
Despite the challenging backdrop, Brenntag maintained strong cash generation, with Q2 free cash flow at EUR 152.9 million (USD 179 million).
The company also reinforced its sustainability credentials, earning an EcoVadis Gold rating and CDP Climate “Leadership” score.
Geopolitical tensions, tariff uncertainties, and unfavourable EUR/USD trends are expected to persist, weighing on end-market demand.
CEO Christian Kohlpaintner emphasized Brenntag’s resilience and focus on executing its “Strategy to Win” initiatives to create new business opportunities and drive structural improvements.
Diversified portfolio, global reach, and innovation-focused ingredient offerings keep it well positioned for long-term growth.
Sign up to receive our email newsletters with the latest news updates and insights from Africa and the World HERE.
